BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2026 9:14:07 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-01-23 05:59 |
|
Peer-Review Started |
|
2026-01-23 06:01 |
|
First Decision by Editorial Office Director |
|
2026-02-03 07:43 |
|
Return for Revision |
|
2026-02-03 07:43 |
|
Revised |
|
2026-02-11 23:33 |
|
Publication Fee Transferred |
|
2026-02-13 05:01 |
|
Second Decision by Editor |
|
2026-03-17 03:07 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-17 07:41 |
|
Articles in Press |
|
2026-03-17 07:41 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-08 09:50 |
|
Publish the Manuscript Online |
|
2026-06-24 09:14 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qi-Sen Li, An-Yin Hu, Shao-Jie Chen, Gong-Jin Yu, Yi Fan, Yi-Gang Chen, She Tian, Ci-Jun Peng and Min Han |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guizhou Provincial Science and Technology Plan Project |
Qian-KH-[2024]-Youth-009 |
|
| Corresponding Author |
Ci-Jun Peng, PhD, Professor, Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, No. 28 Guiyi Street, Guiyang 550001, Guizhou Province, China. doctorpengcijun@163.com |
| Key Words |
Hepatocellular carcinoma; Hepatectomy; Recurrence; Adjuvant therapy; Tyrosine kinase inhibitors; Immune-checkpoint inhibitors; Cohort study |
| Core Tip |
This retrospective cohort study demonstrates that adjuvant targeted and/or immunotherapy can significantly improve recurrence-free survival in hepatocellular carcinoma patients at high risk of recurrence after hepatectomy, compared to surgery alone. The therapy was identified as an independent protective factor against recurrence. While a clear overall survival benefit was not observed in this analysis, the treatment regimen showed a manageable safety profile, with most adverse events being reversible. These findings support the potential role of this adjuvant strategy in improving outcomes for this patient population. |
| Publish Date |
2026-06-24 09:14 |
| Citation |
Li QS, Hu AY, Chen SJ, Yu GJ, Fan Y, Chen YG, Tian S, Peng CJ, Han M. Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy. World J Gastrointest Surg 2026; 18(6): 119272
|
| URL |
https://www.wjgnet.com/1948-9366/full/v18/i6/119272.htm |
| DOI |
https://doi.org/10.4240/wjgs.119272 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
